Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
New Ray Medicine International HoldingHKSE:06108 52 Piotroski F-Score is 5 as of Aug. 26, 2026, which is at its 10-year median of 5.00. GuruFocus rates HKSE:06108 with a GF Score™ of 52/100 and a GF Value™ of HK$1.04 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 647 Healthcare Providers & Services companies, New Ray Medicine International Holding ranks better than 56.41% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
New Ray Medicine International Holding has an F-score of 5 indicating the company's financial situation is typical for a stable company.
New Ray Medicine International Holding (HKSE:06108) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
New Ray Medicine International Holding Piotroski F-Score Related Terms
New Ray Medicine International Holding Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Piotroski F-Score Chart
New Ray Medicine International Holding Annual Data
New Ray Medicine International Holding Piotroski F-Score Competitor Comparison
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding Piotroski F-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
New Ray Medicine International Holding's current Net Income (TTM) was -20.1.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
New Ray Medicine International Holding's current Cash Flow from Operations (TTM) was -54.1.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
New Ray Medicine International Holding's return on assets of this year was -0.03971815. New Ray Medicine International Holding's return on assets of last year was -0.06308546.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
New Ray Medicine International Holding's gearing of this year was 0.00357423. New Ray Medicine International Holding's gearing of last year was 0.00482325.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
New Ray Medicine International Holding's current ratio of this year was 55.94003102. New Ray Medicine International Holding's current ratio of last year was 12.00644405.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
New Ray Medicine International Holding's number of shares in issue this year was 168.009. New Ray Medicine International Holding's number of shares in issue last year was 167.185.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
New Ray Medicine International Holding's gross margin of this year was 0.12386672. New Ray Medicine International Holding's gross margin of last year was 0.12232689.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
New Ray Medicine International Holding's asset turnover of this year was 0.25804626. New Ray Medicine International Holding's asset turnover of last year was 0.19109932.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
1
+
1
+
0
+
1
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
New Ray Medicine International Holding has an F-score of 5 indicating the company's financial situation is typical for a stable company.
New Ray Medicine International Holding (HKSE:06108) has a Piotroski F-Score of 5 as of Aug. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on New Ray Medicine International Holding and its competitors. This is near median its historical median of 5.00. Over the past decade, New Ray Medicine International Holding's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, New Ray Medicine International Holding ranks #282 out of 647 companies in the Healthcare Providers & Services industry, placing it in the top 43.6%.
Is New Ray Medicine International Holding's Piotroski F-Score too high?
New Ray Medicine International Holding's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. New Ray Medicine International Holding's value of 5 is 0% at this industry median. Based on the distribution chart, New Ray Medicine International Holding ranks #282 out of 647 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, New Ray Medicine International Holding has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does New Ray Medicine International Holding's Piotroski F-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, New Ray Medicine International Holding ranks #282 out of 647 companies for Piotroski F-Score. This puts New Ray Medicine International Holding in the upper half of its industry. The industry median Piotroski F-Score is 5.00. New Ray Medicine International Holding's value of 5 is 0% at this benchmark. Historically, New Ray Medicine International Holding's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, New Ray Medicine International Holding has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 647 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. New Ray Medicine International Holding's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on New Ray Medicine International Holding and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Ray Medicine International Holding's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Ray Medicine International Holding stock overvalued right now?
Based on GuruFocus' analysis, New Ray Medicine International Holding (HKSE:06108) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.04, compared to a current price of HK$0.23 — trading 78.4% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Healthcare Providers & Services industry median of 5.00. New Ray Medicine International Holding's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For New Ray Medicine International Holding (HKSE:06108), the current Piotroski F-Score is 5 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?
Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued.
The current stock price of HK$0.23 is trading 78.4% below its estimated GF Value™ of HK$1.04.
GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.
Key valuation signals for HKSE:06108:
Piotroski F-Score: 5 (near median its 10-year median of 5.00)
GF Value™: HK$1.04 vs. price of HK$0.23 (78.4% below fair value)
Industry Position: 0% at the Healthcare Providers & Services median (#282 of 647)
No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
52GF Score
Get the complete analysis for HKSE:06108
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06108 has been successfully added to your 
